Baseline Demographics and Clinical Characteristics Characteristic Mean (SD) Tirzepatide Insulin lispro (n = 708) 15 mg (n = 236) 10 mg (n = 238) 5m g (n = 243) Pooled (n = 717) Age, y 58.2 (9.6) 59.6 (9.4) 58.0 (10.2) 58.6 (9.8) 59.0 (9.7) Women, No. (%) 133 (56.4) 149 (62.6) 144 (59.3) 426 (59.4) 396 (55.9) Men, No. (%) 103 (43.6) 89 (37.4) 99 (40.7) 291 (40.6) 312 (44.1) Race, No. (%)a American Indian or Alaska Native 1 (0.4) 0 0 1 (0.1) 2 (0.3) Asian 2 (0.8) 0 2 (0.8) 4 (0.6) 4 (0.6) Black or African American 11 (4.7) 9 (3.8) 11 (4.5) 31 (4.3) 26 (3.7) Multiple 2 (0.8) 5 (2.1) 0 7 (1.0) 8 (1.1) White 220 (93.2) 224 (94.1) 230 (94.7) 674 (94.0) 668 (94.4) Hispanic or Latino, No. (%)a 149 (63.1) 142 (59.7) 148 (60.9) 439 (61.2) 443 (62.6) Diabetes duration, yb 13.4 (7.6) 13.9 (7.3) 13.4 (6.9) 13.6 (7.2) 14.0 (7.4) Body weight, kg 91.2 (18.7) 89.1 (18.8) 91.7 (17.9) 90.7 (18.5) 90.3 (17.7) BMI 33.0 (5.3) 33.4 (5.5) 33.5 (5.3) 33.3 (5.4) 33.0 (5.2) Use of metformin, No. (%) 201 (85.2) 195 (81.9) 202 (83.1) 598 (83.4) 606 (85.6) Daily insulin glargine dose, median (IQR), IU 47.0 (36.0-61.0) 46.0 (34.0-60.0) 46.0 (36.0-60.0) 46.0 (36.0-60.0) 46.0 (36.0-60.0) Daily insulin glargine dose, median (IQR), IU/kg 0.52 (0.41-0.69) 0.54 (0.41-0.69) 0.51 (0.41-0.66) 0.52 (0.41-0.68) 0.53 (0.42-0.68) HbA1c,% c 8.74 (1.01) 8.78 (0.98) 8.89 (0.97) 8.80 (0.99) 8.80 (0.96) HbA1c >8.5%, No. (%) 132 (55.9) 133 (55.9) 146 (60.1) 411 (57.3) 407 (57.5) Fasting serum glucose, mg/dLd 155.9 (54.3) 155.8 (55.5) 163.3 (59.2) 158.4 (56.4) 156.3 (56.1) eGFR, mL/min/1.73 m2,e 89.3 (19.9) 89.5 (18.0) 89.0 (20.7) 89.3 (19.6) 88.8 (18.8) eGFR <60 mL/min/1.73 m2, No. (%) 24 (10.2) 14 (5.9) 27 (11.1) 65 (9.1) 65 (9.2) Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); eGFR, estimated glomerular filtration rate (calculated with use of the serum creatinineâ€“based Chronic Kidney Disease Epidemiology Collaboration equation); HbA1c, glycated hemoglobin A1c.